# To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

> **NCT01403922** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 80 (actual)

## Conditions studied

- Chronic Hypertension

## Interventions

- **DRUG:** TC-5214
- **DRUG:** TC-5214

## Key facts

- **NCT ID:** NCT01403922
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate
- **Last updated:** 2012-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01403922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01403922, "To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01403922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*